- |||||||||| Lyfnua (gefapixant) / Merck (MSD)
Journal: The Clinical Approach to Chronic Cough. (Pubmed Central) - Mar 6, 2025
Despite these advances, patient responses remain variable, underscoring the ongoing need for research into the pathophysiology and treatment of RCC. This article reviews current investigations and management options in treating chronic cough and RCC.
- |||||||||| Lyfnua (gefapixant) / Merck (MSD)
Enrollment open, HEOR, Real-world evidence: RESTORE: The Real-world Treatment Satisfaction by Gefapixiant in RCC (clinicaltrials.gov) - Jan 29, 2025
P=N/A, N=63, Recruiting,
This trial result should be considered inconclusive given possible issues with treatment compliance. Not yet recruiting --> Recruiting
- |||||||||| morphine sulphate / Generic mfg., Lyfnua (gefapixant) / Merck (MSD), ibuprofen / Generic mfg.
Preclinical, Journal: Pharmacological differences in postoperative cutaneous sensitivity, pain at rest, and movement-induced pain in laparotomized mice. (Pubmed Central) - Nov 13, 2024
The standard analgesics morphine and ibuprofen induced distinct patterns of outcome-dependent effects...We tested the effects of gefapixant, an antitussive drug targeting non-peptidergic nociceptors through P2X3 antagonism, and olcegepant, an antimigraine drug acting as a CGRP antagonist...In conclusion, tactile allodynia, pain at rest, and movement-induced pain after surgery have different pharmacological profiles, and none of the three aspects of postoperative pain can predict the effects of a given intervention on the other two. Combining these measures provides a more realistic view of postoperative pain and has the potential to benefit analgesic development.
- |||||||||| Lyfnua (gefapixant) / Merck (MSD)
Journal: The discovery and development of gefapixant as a novel antitussive therapy. (Pubmed Central) - Oct 10, 2024
This research and personalized treatment approaches are key to optimizing gefapixant therapy, ensuring improved management of chronic cough while reducing adverse effects. However, pharmaceutical trials and proposals must be adapted to align with each regulatory body's specific requirements and concerns.
- |||||||||| Lyfnua (gefapixant) / Merck (MSD)
Enrollment open: Effect of Gefapixant on Cough-related Brain Activity in Patients With Chronic Cough (clinicaltrials.gov) - May 9, 2024
P1, N=31, Recruiting,
A higher percentage of pts receiving gefapixant reported clinically meaningful improvements in LCQ social, psychological, and physical domains vs pbo, supporting the broad benefit of gefapixant on cough-specific quality of life. Not yet recruiting --> Recruiting
- |||||||||| Lyfnua (gefapixant) / Merck (MSD)
Real World Experience of Gefapixant Prescribing (San Diego Convention Center, Area K (Hall H, Ground Level)) - Feb 20, 2024 - Abstract #ATS2024ATS_3717;
Although numbers are small, change in PROs are consistent with that seen in RCTs. Patients appear to respond rapidly and provide positive qualitative feedback.
- |||||||||| Lyfnua (gefapixant) / Merck (MSD)
Journal: Gefapixant for Chronic Cough. (Pubmed Central) - Feb 13, 2024
Patients appear to respond rapidly and provide positive qualitative feedback. No abstract available
- |||||||||| Lyfnua (gefapixant) / Merck (MSD)
Review, Journal: Is there a biochemical basis for purinergic P2X3 and P2X4 receptor antagonists to be considered as anti-seizure medications? (Pubmed Central) - Feb 11, 2024
While compounds interacting with these receptors have been approved for use as medicines (e.g., gefapixant for cough) and continue to be explored for a number of diseases (e.g., pain, cancer), there have been no purinergic receptor antagonists that have been advanced for epilepsy...The discovery of new and selective antagonists for P2X3 and P2X4 receptors is ongoing, armed with new structural data to guide rational design. The availability of safe, brain-penetrant compounds will likely encourage the clinical exploration of epilepsy as a disease entity.
- |||||||||| Lyfnua (gefapixant) / Merck (MSD)
Review, Journal: The Therapeutic Landscape in Chronic Cough. (Pubmed Central) - Dec 21, 2023
The availability of safe, brain-penetrant compounds will likely encourage the clinical exploration of epilepsy as a disease entity. In recent years, there has been a substantial increase in the development of antitussive therapies and the first new
- |||||||||| Lyfnua (gefapixant) / Merck (MSD)
Journal: Chronic cough relief by allosteric modulation of P2X3 without taste disturbance. (Pubmed Central) - Sep 20, 2023
While being therapeutically comparable to the newly licensed P2X3 RCC drug gefapixant, quercetin and PSFL2915 do not have an adverse effect on taste as gefapixant does. Thus, allosteric modulation of P2X3 via IP-HD may be a druggable strategy to alleviate RCC.
- |||||||||| Lyfnua (gefapixant) / Merck (MSD)
Journal: Gefapixant for Refractory or Unexplained Chronic Cough? (Pubmed Central) - Sep 11, 2023
Compared with placebo, gefapixant (45 mg orally twice daily) led to modest improvements in cough frequency, cough severity, and cough-specific quality of life but increased taste-related adverse events. No abstract available
- |||||||||| Lyfnua (gefapixant) / Merck (MSD)
Journal: Efficacy of gefapixant, a P2X antagonist, for lung cancer-related cough: a case report. (Pubmed Central) - Sep 2, 2023
Gefapixant (P2X antagonist) add-on at a dose of 90?mg/day (45?mg twice daily as the usual dosage in Japan) improved her cough as indicated by an improvement in the visual analog scale for cough from 70 to 20?mm and in the Japanese version of the Leicester Cough Questionnaire from 8.2 to 16.3, despite a deterioration in lung cancer after 2 weeks. There are no current guidelines for cough accompanied by lung cancer; however, our findings suggest that P2X inhibition is a potent therapeutic option for lung cancer-related cough.
- |||||||||| Lyfnua (gefapixant) / Merck (MSD), eliapixant (BAY 1817080) / Evotec
Retrospective data, Review, Journal: Efficacy and safety of pharmacotherapy for refractory or unexplained chronic cough: a systematic review and network meta-analysis. (Pubmed Central) - Aug 4, 2023
In the network meta-analysis, gefapixant is the most effective treatment for patients with RCC (The Surface Under the Cumulative Ranking Curves (SUCRA) is 0.711 in LCQ, 0.983 in 24 h cough frequency, and 0.786 in cough severity VAS)...Eliapixant and lesogaberan had better efficacy than placebo in cough severity VAS...Further research is needed to determine the potential beneficiary population for optimizing the pharmacological management of chronic cough. National Natural Science Foundation of China (81870079), Guangdong Science and Technology Project (2021A050520012), Incubation Program of National Science Foundation for Distinguished Young Scholars (GMU2020-207).
- |||||||||| Lyfnua (gefapixant) / Merck (MSD)
Cough drugs and trials: truly novel medicines or is it all a placebo effect? (Coral 4+5) - Jun 17, 2023 - Abstract #ERS2023ERS_3024;
Other classes of drugs are emerging, including sodium channel blockers, NK1 antagonists, NMDA antagonists, TRPM8 agonists and opioid receptor agonists. This session will raise awareness of the above developments in this field.; Epidemiology; General respiratory patient care; Physiology
- |||||||||| Lyfnua (gefapixant) / Merck (MSD)
Patient-reported cough severity in women with chronic cough and stress urinary incontinence treated with gefapixant (PS-8 in poster area) - Jun 17, 2023 - Abstract #ERS2023ERS_2744;
Pulmonary function testing; Physiology; Imaging; Endoscopy and interventional pulmonology; Surgery; Cell and molecular biology; General respiratory patient care; Epidemiology Pulmonary function testing; Physiology; Imaging; Endoscopy and interventional pulmonology; Surgery; Cell and molecular biology; General respiratory patient care; Epidemiology
- |||||||||| Lyfnua (gefapixant) / Merck (MSD)
Early cough severity changes over the first 4 weeks of treatment with gefapixant in two phase 3 studies (PS-8 in poster area) - Jun 17, 2023 - Abstract #ERS2023ERS_2740;
Pulmonary function testing; Physiology; Imaging; Endoscopy and interventional pulmonology; Surgery; Cell and molecular biology; General respiratory patient care; Epidemiology Pulmonary function testing; Physiology; Imaging; Endoscopy and interventional pulmonology; Surgery; Cell and molecular biology; General respiratory patient care; Epidemiology
- |||||||||| camlipixant (BLU-5937) / Bellus Health, AstraZeneca, Lyfnua (gefapixant) / Merck (MSD)
P2X3 Potentiates IgE Mediated Mast Cell Function (P515) (Exhibit Hall; Poster Board No. P515) - Apr 11, 2023 - Abstract #IMMUNOLOGY2023IMMUNOLOGY_897;
Furthermore, P2X3 knock-out mice showed reduced IL-6 compared to wild-type mice in the PSA model. Interestingly, inhibition or deletion of the P2X3 receptor showed no effect on mast cell degranulation in vitro and did not reduce hypothermia during PSA.
- |||||||||| Lyfnua (gefapixant) / Merck (MSD)
Journal: Gefapixant in the treatment of chronic coughing (Pubmed Central) - Mar 27, 2023
Interestingly, inhibition or deletion of the P2X3 receptor showed no effect on mast cell degranulation in vitro and did not reduce hypothermia during PSA. No abstract available
- |||||||||| Lyfnua (gefapixant) / Merck (MSD)
A Phase 3b Trial of Gefapixant, A P2X3-receptor Antagonist, in Women With Chronic Cough and Stress Urinary Incontinence (Walter E. Washington Convention Center, Area D, Hall C (Lower Level)) - Mar 25, 2023 - Abstract #ATS2023ATS_4866;
P3b
Carcainium, a non-selective sodium channel blocker that has shown efficacy in CC patients, given by intratracheal route at 3 Gefapixant was superior to placebo in reducing mean daily cSUI episodes and improving cough severity after 12 weeks in individuals with RCC or UCC and cSUI, with a similar safety profile to that in previous studies.
- |||||||||| Lyfnua (gefapixant) / Merck (MSD), eliapixant (BAY 1817080) / Evotec, CE-224535 / Pfizer
Review, Journal: P2X receptors: Insights from the study of the domestic dog. (Pubmed Central) - Dec 5, 2022
The article will also discuss the characterization of single nucleotide polymorphisms in the canine P2RX7 gene, and contrast this variation to the canine P2RX4 gene, which is largely conserved between dogs. Finally, this article will outline published examples of the use of dogs to study the pharmacokinetics of P2X7 and P2X3 antagonists, and how they have contributed to the preclinical testing of antagonists to human P2X7, CE-224,535, and human P2X3, Gefapixant (AF-219, MK-7264) and Eliapixant (BAY, 1817080), with Gefapixant gaining recent approval for use in the treatment of refractory chronic cough in humans.
- |||||||||| Lyfnua (gefapixant) / Merck (MSD)
PK/PD data, Journal: Effects of Renal Impairment on the Pharmacokinetics of Gefapixant, a P2×3 Receptor Antagonist. (Pubmed Central) - Oct 19, 2022
The data from this trial informed the enrollment of Phase 3 clinical trials that evaluated the efficacy and safety of gefapixant in over 2,000 participants with refractory or unexplained chronic cough. Those efficacy and safety data, combined with analysis of population pharmacokinetics from across the entire development program, will be used to evaluate the magnitude of the renal impairment effect in the refractory or unexplained chronic cough population and to determine any dose adjustment recommendations.
- |||||||||| Journal: Managed care considerations for the treatment of chronic cough. (Pubmed Central) - Oct 12, 2022
These targeted agents may have improved efficacy and safety profiles, helping fill unmet treatment needs. If approved, managed care organizations must develop formulary placement and utilization management criteria based on clinical guideline recommendations, expert opinion, and cost-effectiveness analyses to support the clinically appropriate use of these targeted therapies for best patient outcomes.
- |||||||||| Lyfnua (gefapixant) / Merck (MSD)
Clinical, P3 data, Journal: A phase 3, randomized, double-blind, clinical study to evaluate the long-term safety and efficacy of gefapixant in Japanese adult participants with refractory or unexplained chronic cough. (Pubmed Central) - Sep 29, 2022
P3
If approved, managed care organizations must develop formulary placement and utilization management criteria based on clinical guideline recommendations, expert opinion, and cost-effectiveness analyses to support the clinically appropriate use of these targeted therapies for best patient outcomes. Gefapixant had an acceptable safety profile, with no serious treatment-related AEs in Japanese participants.
|
